| Abstrakt: |
Background: One of the leading cause of mortality in various connective tissue diseases (CTD) like systemic sclerosis (SSc) is Interstitial lung disease (ILD). The various CTD which may present as ILD include systemic sclerosis (SSc), rheumatoid arthritis (RA), dermatomyositis (DM), primary Sjogren’s syndrome (pSS), mixted connective tissue disease (MCTD) and systemic lupus erythematosus (SLE). Objective: To compare the safety and tolerability of two salts of mycophenolate, i.e. mycophenolate mofetil and mycophenolate sodium in our patients with CTD-ILD. Patients and Method: Ourstudy was retrospective observational study; involving 70 patients diagnosed with CTD-ILD and was treated with two formulations of Mycophenolate (Mofetil and Sodium) minimum for six months with at least one follow-up during the period of May 2013 to April 2017 at tertiary care hospital from India. Fifty-six patients received MPS and fourteen patients received MMF. The details of patients obtained from case records were recorded in a proforma. Statistical analysis was performed using Graph pad for frequency, mean and percentages. Results: In our study, most of the patients received Mycophenolate sodium (n=56) with the BD dose regimen of 720 mg (n=36), 540 mg (n=18) and 180 mg (n=2). Patients treated with MMF 1000 mg (n=12) and 750 mg (n=2) as BD dose regimen. The adverse events reported in this study were GI (diarrhoea), herpes zoster infection, cytopenia, malignancies or any other infections. The incidence of diarrhea is most commonly observed in this study population. Out of 26 reported cases, 14 patients had an episode of diarrhea at least once and 12 patients had diarrhea attack twice the preceding year. Conclusions: Both formulations of Mycophenolate were tolerated well, and have low-dose corticosteroid use with no discontinuation of therapy. [ABSTRACT FROM AUTHOR] |
